Expanding Oncology Partnerships Niowave's recent collaborations with AstraZeneca and Aktis Oncology highlight significant growth in the cancer therapy sector, particularly in supplying alpha emitters like Actinium-225 for next-generation treatments, presenting opportunities for suppliers and distributors focused on radiopharmaceuticals.

Government Collaboration & Domestic Supply Partnering with the National Nuclear Security Administration to develop domestically produced molybdenum-99 positions Niowave as a key contributor to secure radiological supplies, opening avenues for government agencies and contractors seeking reliable, non-reactor based isotope sources.

Innovative Technology Use By utilizing superconducting linacs instead of nuclear reactors, Niowave offers a cost-effective and scalable isotope production method that appeals to organizations aiming to reduce regulatory burdens while maintaining high-quality radiochemical outputs.

Growing Operational Capacity With a recent increase of 35 employees and ongoing investments in Lansing, Niowave’s expanding workforce and infrastructure indicate an increasing production capacity, creating sales opportunities for equipment suppliers, automation technology providers, and services supporting scaling operations.

Focus on Emerging Medical Applications Active clinical trials and partnerships targeting bladder cancer and other oncological indications suggest a demand for specialized radiochemistry materials, creating potential collaborations with research organizations and pharmaceutical firms developing advanced radiopharmaceutical products.